PL3511330T3 - Syntetyczny związek pośredni użyteczny w wytwarzaniu triazolopirydynowych inhibitorów c-Met - Google Patents

Syntetyczny związek pośredni użyteczny w wytwarzaniu triazolopirydynowych inhibitorów c-Met

Info

Publication number
PL3511330T3
PL3511330T3 PL19151824T PL19151824T PL3511330T3 PL 3511330 T3 PL3511330 T3 PL 3511330T3 PL 19151824 T PL19151824 T PL 19151824T PL 19151824 T PL19151824 T PL 19151824T PL 3511330 T3 PL3511330 T3 PL 3511330T3
Authority
PL
Poland
Prior art keywords
triazolopyridine
preparation
synthetic intermediate
intermediate useful
met inhibitors
Prior art date
Application number
PL19151824T
Other languages
English (en)
Inventor
Wei-Guo Su
Hong Jia
Guangxiu Dai
Original Assignee
Hutchison Medipharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44226181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3511330(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hutchison Medipharma Limited filed Critical Hutchison Medipharma Limited
Publication of PL3511330T3 publication Critical patent/PL3511330T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
PL19151824T 2009-12-31 2010-12-30 Syntetyczny związek pośredni użyteczny w wytwarzaniu triazolopirydynowych inhibitorów c-Met PL3511330T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN2009076321 2009-12-31
EP13198224.1A EP2719699B1 (en) 2009-12-31 2010-12-30 Certain triazolopyrazines, compositions thereof and methods of use therefor
PCT/CN2010/080499 WO2011079804A1 (en) 2009-12-31 2010-12-30 Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor
EP10840591.1A EP2519524A4 (en) 2009-12-31 2010-12-30 CERTAIN TRIAZOLOPYRIDINE AND TRIAZOLOPYRZINE, COMPOSITIONS AND METHOD OF USE
EP19151824.0A EP3511330B1 (en) 2009-12-31 2010-12-30 Synthetic intermediate useful in the preparation of triazolopyridine c-met inhibitors
EP15170608.2A EP2966075B1 (en) 2009-12-31 2010-12-30 Certain triazolopyridines, compositions thereof and their use in the treatment of cancer.

Publications (1)

Publication Number Publication Date
PL3511330T3 true PL3511330T3 (pl) 2021-04-19

Family

ID=44226181

Family Applications (3)

Application Number Title Priority Date Filing Date
PL20199091.8T PL3795573T3 (pl) 2009-12-31 2010-12-30 Niektóre triazolopirazyny, ich kompozycje i sposoby ich zastosowania
PL13198224T PL2719699T3 (pl) 2009-12-31 2010-12-30 Pewne triazolopirazyny, ich kompozycje i sposoby ich stosowania
PL19151824T PL3511330T3 (pl) 2009-12-31 2010-12-30 Syntetyczny związek pośredni użyteczny w wytwarzaniu triazolopirydynowych inhibitorów c-Met

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL20199091.8T PL3795573T3 (pl) 2009-12-31 2010-12-30 Niektóre triazolopirazyny, ich kompozycje i sposoby ich zastosowania
PL13198224T PL2719699T3 (pl) 2009-12-31 2010-12-30 Pewne triazolopirazyny, ich kompozycje i sposoby ich stosowania

Country Status (38)

Country Link
US (9) US8987269B2 (pl)
EP (5) EP3511330B1 (pl)
JP (5) JP5337313B2 (pl)
KR (3) KR101434766B1 (pl)
CN (3) CN106432225B (pl)
AU (2) AU2010338712B2 (pl)
BR (1) BR112012016129B1 (pl)
CA (1) CA2785749C (pl)
CL (1) CL2012001752A1 (pl)
CO (1) CO6612235A2 (pl)
CU (1) CU24167B1 (pl)
CY (2) CY1118250T1 (pl)
DK (3) DK3795573T3 (pl)
DO (1) DOP2012000188A (pl)
EA (2) EA025466B1 (pl)
EC (1) ECSP12012011A (pl)
ES (4) ES2840454T3 (pl)
GT (1) GT201200220A (pl)
HR (3) HRP20221090T1 (pl)
HU (3) HUE025504T2 (pl)
IL (2) IL220433B (pl)
LT (1) LT3795573T (pl)
ME (1) ME02211B (pl)
MX (2) MX386852B (pl)
MY (1) MY179933A (pl)
NI (1) NI201200118A (pl)
NZ (1) NZ601128A (pl)
PE (3) PE20160588A1 (pl)
PH (1) PH12012501355A1 (pl)
PL (3) PL3795573T3 (pl)
PT (3) PT3511330T (pl)
RS (3) RS61281B1 (pl)
SG (1) SG181781A1 (pl)
SI (2) SI2719699T1 (pl)
SM (3) SMT202000693T1 (pl)
UA (1) UA107822C2 (pl)
WO (1) WO2011079804A1 (pl)
ZA (1) ZA201205730B (pl)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101434766B1 (ko) * 2009-12-31 2014-08-26 허치슨 메디파르마 리미티드 특정 트리아졸로피리딘 및 트리아졸로피라진, 이들의 조성물 및 이들의 사용 방법
DK2571878T3 (en) 2010-05-17 2019-02-11 Indian Incozen Therapeutics Pvt Ltd Hitherto unknown 3,5-DISUBSTITUTED-3H-IMIDAZO [4,5-B] PYRIDINE AND 3,5- DISUBSTITUTED -3H- [1,2,3] TRIAZOL [4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN CHINES
CN103030654A (zh) * 2011-10-09 2013-04-10 济南赛文医药技术有限公司 一种小分子c-Met蛋白激酶抑制剂
CN102516046A (zh) * 2011-11-22 2012-06-27 太仓市运通化工厂 一种2-溴丙醛的合成方法
KR20140144726A (ko) * 2012-03-30 2014-12-19 리젠 파마슈티컬스 소시에떼 아노님 C-met 단백질 키나제의 조절제로서의 신규한 3,5-디치환-3h-이미다조[4,5-b]피리딘 및 3,5- 디치환 -3h-[1,2,3]트리아졸로[4,5-b] 피리딘 화합물
CA2776178A1 (en) * 2012-04-05 2013-10-05 Hydro-Quebec Ionic compounds
KR101745741B1 (ko) 2012-08-13 2017-06-12 한국화학연구원 신규한 트리아졸로 피라진 유도체 및 그의 용도
EP2944637B1 (en) 2013-01-11 2020-02-19 FUJIFILM Corporation Nitrogen-containing heterocylic compound or salt thereof
EP3342770B1 (en) 2013-03-06 2022-03-30 AstraZeneca AB Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
CN103265468A (zh) * 2013-06-17 2013-08-28 连云港盛和生物科技有限公司 一种2,4-二甲基-3-吡咯甲酸乙酯的合成方法
EP2818471A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5
EP3053923B1 (en) 2013-09-30 2018-04-11 Korea Research Institute of Chemical Technology Triazolopyrazine derivatives as tyrosin kinase inhibitors
ES2654931T3 (es) * 2013-12-26 2018-02-15 Ignyta, Inc. Derivados de pirazolo[1,5-a]piridina y procedimientos de uso de los mismos
JP2016048495A (ja) * 2014-08-28 2016-04-07 京セラ株式会社 携帯端末、レコメンドプログラム、レコメンドシステムおよびレコメンド方法
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
CN109369656B (zh) * 2015-12-31 2021-05-07 上海医药集团股份有限公司 喹啉类化合物硫酸盐的晶型、制备方法、组合物与应用
GB201616116D0 (en) 2016-09-22 2016-11-09 Astrazeneca Ab Use of c-Met inhibitors to treat cancers harbouring MET mutations
KR20180092096A (ko) 2017-02-08 2018-08-17 에이비온 주식회사 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
WO2018160892A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
HUE073004T2 (hu) 2017-03-01 2025-12-28 Achillion Pharmaceuticals Inc Aril, heteroaril és heterociklusos gyógyszeripari vegyületek egészségügyi rendellenesség kezelésére
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
CN108570053A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元并六元杂环化合物、制备方法、中间体、组合和应用
KR101924801B1 (ko) 2017-08-16 2018-12-04 한국원자력의학원 트리아졸로피리딘계 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 조성물
HU231333B1 (hu) 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok
HU231414B1 (hu) 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
US11814363B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Morphic forms of danicopan
WO2020051532A2 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
IL281283B2 (en) * 2018-09-11 2024-01-01 Astrazeneca Ab Improved method for the production of 3-[(1S)-1-imidazolo[1,2-A]pyridine-6-ylethyl]-5-(1-methylpyrazol-1-YL]triazolo[4,5-B]pyrazine and polymeric forms His
AU2019346464A1 (en) 2018-09-25 2021-04-08 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor D inhibitors
EP3873905A4 (en) * 2018-10-30 2022-08-17 Repare Therapeutics Inc. COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING COMPOUNDS AND THEIR USE AS ATR KINASE INHIBITORS
AU2019395282A1 (en) 2018-12-14 2021-07-08 Beta Pharma, Inc. Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereof
EP3898617A4 (en) 2018-12-17 2022-08-17 Achillion Pharmaceuticals, Inc. TARGETED DOSAGE FOR THE TREATMENT OF COMPLEMENT INDUCED DISORDERS
CN113795249B (zh) 2019-03-22 2025-02-25 艾其林医药公司 用于治疗补体介导的病症的药物化合物
KR20220035925A (ko) * 2019-07-22 2022-03-22 리페어 세라퓨틱스 인크. Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체
EP4107166A4 (en) * 2020-02-20 2024-06-26 Achillion Pharmaceuticals, Inc. HETEROARYL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D-MEDIATED DISORDERS
WO2021229605A1 (en) * 2020-05-14 2021-11-18 Dr. Reddy's Laboratories Limited Process for preparation of savolitinib and its intermediates
JP2023543990A (ja) * 2020-09-28 2023-10-19 コデクシス， インコーポレイテッド キラルアミンを合成するための操作された生体触媒および方法
JP2023554393A (ja) * 2020-12-16 2023-12-27 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
KR102659095B1 (ko) 2021-01-08 2024-04-19 에이비온 주식회사 트리아졸로피라진 유도체 화합물을 유효성분으로 하는 약학적 조성물의 태블릿정의 제조방법
CN113278019A (zh) * 2021-05-31 2021-08-20 河南偶联生物科技有限公司 一种咪唑并[1,2-a]吡啶类化合物的合成方法
WO2023278326A1 (en) 2021-06-28 2023-01-05 Blueprint Medicines Corporation Cdk2 inhibitors
CA3248309A1 (en) * 2022-04-20 2023-10-26 Engrail Therapeutics, Inc. γ-AMINOBUTYRIC ACID RECEPTOR MODULATOR SALTS, PARTICLES AND THEIR USES
CA3261476A1 (en) 2022-07-08 2024-01-11 Astrazeneca Ab Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Combination with HGF Receptor Inhibitors for the Treatment of Cancer
AU2023312919A1 (en) * 2022-07-29 2025-03-06 Baylor College Of Medicine Neurotrophic receptor tyrosine kinase (ntrk) inhibitors and methods using same
CN115611802B (zh) * 2022-12-02 2023-03-14 北京迪泰医药科技有限公司 一种3-乙酰基-2-氯吡啶的合成方法
JP2026501700A (ja) * 2023-01-04 2026-01-16 ブループリント メディシンズ コーポレイション Ｃｄｋ２阻害剤
GB202300923D0 (en) * 2023-01-20 2023-03-08 Macfarlan Smith Ltd Novel polymorphic forms of savolitinib
WO2024263860A1 (en) * 2023-06-22 2024-12-26 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US5977134A (en) * 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2333040A1 (en) * 1998-05-26 1999-12-02 Merck & Co., Inc. Imidazopyridine thrombin inhibitors
JP2000119250A (ja) * 1998-08-11 2000-04-25 Takeda Chem Ind Ltd 環状アミド化合物、その製造法、中間体及び除草剤
WO2004092177A1 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
MXPA06000091A (es) * 2003-07-02 2006-04-07 Sugen Inc Arilmetiltriazolo e imidazopirazinas como inhibidores de c-met.
US7122548B2 (en) 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
JP2007504243A (ja) 2003-09-03 2007-03-01 ニューロジェン・コーポレーション ５−アリール−ピラゾロ［４，３−ｄ］ピリミジン類、ピリジン類、ピラジン類及び関連化合物
NZ553267A (en) 2004-07-27 2010-09-30 Sgx Pharmaceuticals Inc Pyrrolo-pyridine kinase modulators
EP1786811A2 (en) 2004-08-18 2007-05-23 Pharmacia & Upjohn Company LLC Triazolopyridine compounds
EP1853602B1 (en) * 2005-02-16 2010-07-14 AstraZeneca AB Chemical compounds
CN101119996A (zh) * 2005-02-16 2008-02-06 阿斯利康(瑞典)有限公司 化学化合物
EP1963329B1 (en) 2005-11-30 2013-01-23 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
HRP20170103T1 (hr) 2005-12-21 2017-03-24 Janssen Pharmaceutica N.V. Triazolopiridazini kao modulatori tirozin kinaze
NL2000613C2 (nl) * 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
WO2007138472A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Triazolopyridazine derivatives
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
JP2010500365A (ja) 2006-08-07 2010-01-07 インサイト・コーポレイション キナーゼ阻害剤としてのトリアゾロトリアジン
WO2008036272A1 (en) 2006-09-18 2008-03-27 Vertex Pharmaceuticals Incorporated HETEROCYCLIC INHIBITORS OF c-MET AND USES THEREOF
EA200970403A1 (ru) 2006-10-23 2009-10-30 ЭсДжиЭкс ФАРМАСЬЮТИКАЛЗ, ИНК. Бициклические триазолы в качестве модуляторов протеинкиназы
AU2007309237B2 (en) * 2006-10-23 2012-03-22 Sgx Pharmaceuticals, Inc. Triazolo-pyridazine protein kinase modulators
WO2008064157A1 (en) 2006-11-22 2008-05-29 Incyte Corporation Imidazotriazines and imidazopyrimidines as kinase inhibitors
JP4785881B2 (ja) * 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
AU2008237019A1 (en) 2007-04-10 2008-10-16 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US8148369B2 (en) 2007-05-10 2012-04-03 Janssen Pharmaceutica Nv Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
WO2009105782A1 (en) * 2008-02-21 2009-08-27 Sequoia Pharmaceuticals, Inc. Hiv protease inhibitor and cytochrome p450 inhibitor combinations
BRPI0908504A2 (pt) 2008-02-28 2015-08-11 Novatis Ag Compostos derivados de 3-metil-imidazo[1,2-b]piridazina, uso dos mesmos e composição farmacêutica
JP2011520986A (ja) 2008-05-22 2011-07-21 アムジエン・インコーポレーテツド タンパク質キナーゼ阻害薬としての複素環類
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
MX2012001838A (es) * 2009-08-12 2012-02-29 Novartis Ag Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
KR20120089463A (ko) * 2009-08-20 2012-08-10 노파르티스 아게 헤테로시클릭 옥심 화합물
KR101434766B1 (ko) * 2009-12-31 2014-08-26 허치슨 메디파르마 리미티드 특정 트리아졸로피리딘 및 트리아졸로피라진, 이들의 조성물 및 이들의 사용 방법
DK2571878T3 (en) 2010-05-17 2019-02-11 Indian Incozen Therapeutics Pvt Ltd Hitherto unknown 3,5-DISUBSTITUTED-3H-IMIDAZO [4,5-B] PYRIDINE AND 3,5- DISUBSTITUTED -3H- [1,2,3] TRIAZOL [4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN CHINES

Also Published As

Publication number Publication date
KR20170098324A (ko) 2017-08-29
MX336996B (es) 2016-02-09
PL3795573T3 (pl) 2022-11-21
GT201200220A (es) 2014-12-22
HRP20150952T1 (hr) 2015-10-09
EP2519524A1 (en) 2012-11-07
HRP20202017T1 (hr) 2021-02-19
US20210154192A1 (en) 2021-05-27
US9956218B2 (en) 2018-05-01
PE20130375A1 (es) 2013-04-10
BR112012016129A2 (pt) 2016-05-31
US20180263977A1 (en) 2018-09-20
US20200179377A1 (en) 2020-06-11
MY179933A (en) 2020-11-19
JP2018009004A (ja) 2018-01-18
ME02211B (me) 2016-02-20
US11896592B2 (en) 2024-02-13
AU2010338712B2 (en) 2015-04-02
CY1118250T1 (el) 2017-06-28
EP3511330B1 (en) 2020-09-30
CN102906092A (zh) 2013-01-30
PH12012501355A1 (en) 2012-12-17
DK2719699T3 (en) 2015-08-24
AU2015203480B2 (en) 2017-10-26
BR112012016129B1 (pt) 2020-11-03
CU24167B1 (es) 2016-03-31
CN102906092B (zh) 2016-08-03
EP2966075B1 (en) 2019-02-27
DK3511330T3 (da) 2020-12-21
SI2719699T1 (sl) 2015-12-31
IL239997A (en) 2017-11-30
RS54217B1 (sr) 2015-12-31
ES2546635T3 (es) 2015-09-25
IL239997A0 (en) 2015-08-31
MX2012007756A (es) 2012-11-06
HK1216880A1 (en) 2016-12-09
US20240139182A1 (en) 2024-05-02
JP2013516393A (ja) 2013-05-13
US10512645B2 (en) 2019-12-24
CL2012001752A1 (es) 2013-01-25
WO2011079804A1 (en) 2011-07-07
US20120264739A1 (en) 2012-10-18
EP2719699B1 (en) 2015-07-08
ES2927146T3 (es) 2022-11-02
EP3511330A1 (en) 2019-07-17
EP3795573A1 (en) 2021-03-24
HRP20221090T1 (hr) 2022-11-25
KR20140059307A (ko) 2014-05-15
US8987269B2 (en) 2015-03-24
EP2719699A1 (en) 2014-04-16
KR20120125261A (ko) 2012-11-14
JP2013209418A (ja) 2013-10-10
PT3511330T (pt) 2020-12-24
KR101905350B1 (ko) 2018-11-30
EA025466B1 (ru) 2016-12-30
JP2016155848A (ja) 2016-09-01
AU2010338712A1 (en) 2012-07-12
CU20120101A7 (es) 2012-10-15
PT3795573T (pt) 2022-09-15
JP5337313B2 (ja) 2013-11-06
HUE059696T2 (hu) 2022-12-28
LT3795573T (lt) 2022-11-10
AU2015203480A1 (en) 2015-07-16
RS63612B1 (sr) 2022-10-31
JP6194046B2 (ja) 2017-09-06
SMT202200371T1 (it) 2022-11-18
JP6486999B2 (ja) 2019-03-20
IL220433B (en) 2018-01-31
PT2719699E (pt) 2015-09-30
SG181781A1 (en) 2012-07-30
ES2726152T3 (es) 2019-10-02
US10946014B2 (en) 2021-03-16
US20170027934A1 (en) 2017-02-02
ZA201205730B (en) 2016-01-27
NZ601128A (en) 2014-12-24
HUE025504T2 (en) 2016-02-29
RS61281B1 (sr) 2021-02-26
HUE052828T2 (hu) 2021-05-28
EA030141B1 (ru) 2018-06-29
SI3511330T1 (sl) 2021-01-29
ECSP12012011A (es) 2012-10-30
EA201691461A1 (ru) 2017-01-30
KR101771299B1 (ko) 2017-08-24
SMT202000693T1 (it) 2021-01-05
PL2719699T3 (pl) 2016-01-29
CN106117248A (zh) 2016-11-16
CN106117248B (zh) 2019-01-22
EP3795573B1 (en) 2022-07-06
CN106432225B (zh) 2019-02-19
MX386852B (es) 2025-03-19
CA2785749C (en) 2017-11-28
JP2019108345A (ja) 2019-07-04
US20150368271A1 (en) 2015-12-24
CA2785749A1 (en) 2011-07-07
UA107822C2 (xx) 2015-02-25
HK1194071A1 (en) 2014-10-10
US20250099462A1 (en) 2025-03-27
NI201200118A (es) 2013-01-24
PE20211094A1 (es) 2021-06-14
US8507487B2 (en) 2013-08-13
CO6612235A2 (es) 2013-02-01
CN106432225A (zh) 2017-02-22
KR101434766B1 (ko) 2014-08-26
SMT201500213B (it) 2015-10-30
CY1123777T1 (el) 2022-03-24
US20120245178A1 (en) 2012-09-27
DK3795573T3 (da) 2022-09-19
DOP2012000188A (es) 2012-12-31
ES2840454T3 (es) 2021-07-06
JP6647434B2 (ja) 2020-02-14
EP2966075A1 (en) 2016-01-13
EA201200951A1 (ru) 2013-09-30
EP2519524A4 (en) 2013-07-03
PE20160588A1 (es) 2016-07-09

Similar Documents

Publication Publication Date Title
HUE052828T2 (hu) Szintetikus köztitermék, amely triazolopiridin c-Met gátlók elõállítására használható
LT3511330T (lt) Sintetinis tarpinis junginys, naudotinas triazolpiridino c-met inhibitorių paruošimui
IL220091A0 (en) Pcsk9 antagonists
PL2575504T3 (pl) Kompozycja odżywcza wykazująca właściwości immunologiczne
ZA201204266B (en) Antibody formulation
IL214956A0 (en) Antibody formulation
ZA201202906B (en) Novel naphthyridine derivatives and the use thereof as kinase inhibitors
IL219537A0 (en) Antibody formulation
EP2600760A4 (en) IMPROVED LARYNGOSCOPY
ZA201107963B (en) Dentifrice composition
ZA201303811B (en) Triazolopyridine compounds
ZA201303661B (en) Cleansing composition
ZA201004145B (en) Imiquimod formulation
GB0907003D0 (en) Formulation
EP2620160A4 (en) COMPOSITIONS FOR ORAL ADMINISTRATION
IL219603A0 (en) Imidazopyridine derivatives
GB201018083D0 (en) Absorbant Composition
EP2444401A4 (en) NEW IMIDAZOPYRIDINE COMPOUND
GB0911213D0 (en) Formulation
GB0907410D0 (en) Formulation
GB201001022D0 (en) Play article
GB0910593D0 (en) Carpet rail
GB201005758D0 (en) Buffet train
GB0902472D0 (en) Formulation
GB0906291D0 (en) Formulation